December 7, 2010. FDA Advisory Committee members often ask for post-market studies. In this case, that could be dangerous.
Read More »On Medical Treatments & Products
Testimony at FDA on Gastric LAP-BAND
December 3, 2010. My name is Jessica Resas, and I am a lap band patient. In October of 2009, I had a lap band inserted inside me. Now I want my life back.
Read More »NCHR Testimony at FDA on Gastric LAP-BAND
December 3, 2010. In their newly proposed label, Allergan indicated a “caution” (not a warning) for patients with autoimmune diseases or symptoms, and did NOT mention a family history of those conditions.
Read More »NCHR Testimony at the FDA Advisory Committee Meeting on Lorcaserin
September 16, 2010. The studies are an important reminder that behavior modification is a safe and effective alternative to diet pills. Lorcaserin does not appear to be effective for most patients, and especially not for most African-American or Latino patients. More extensive research is needed on the risks.
Read More »NCHR Testimony at FDA Advisory Committee Meeting on Meridia
September 15, 2010. Meridia is not saving lives and on average harms more patients than it helps. Most people taking Meridia don’t lose much weight, even in the best of circumstances.
Read More »